Phase 2 Clinical Trial of Tanespimycin in Patients With Advanced Malignancies After Failure of Previous Anti-Cancer Therapy Regimens Who Have Participated on a Prior Protocol Investigating Tanespimycin.

Trial Profile

Phase 2 Clinical Trial of Tanespimycin in Patients With Advanced Malignancies After Failure of Previous Anti-Cancer Therapy Regimens Who Have Participated on a Prior Protocol Investigating Tanespimycin.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2014

At a glance

  • Drugs Tanespimycin (Primary)
  • Indications Cancer
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb; Kosan Biosciences
  • Most Recent Events

    • 05 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Apr 2013 Planned end date changed from 1 Mar 2009 to 1 Feb 2014 as reported by ClinicalTrials.gov.
    • 11 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top